Lynch Syndrome Screening Should Be Considered for All Patients With Newly Diagnosed Endometrial Cancer

Lynch syndrome (LS) is an autosomal dominant inherited disorder caused by germline mutations in DNA mismatch repair (MMR) genes. Mutation carriers are at substantially increased risk of developing cancers of the colorectum and endometrium, among others. Given recent recommendations for universal, cost-effective screening of all patients with newly diagnosed colorectal cancer using MMR protein immunohistochemistry, we evaluated MMR protein expression in a series of endometrial cancers in the general population. A total of 605 consecutive cases of primary endometrial cancer at a single institution (1997 to 2013) were evaluated regardless of age, family history, or histologic features. Evaluation methods consisted of immunohistochemistry for the MMR proteins MLH1, MSH2, MSH6, and PMS2, followed by DNA methylation analysis for cases with MLH1/PMS2 deficiency. Germline mutation testing was performed on a subset of cases. Forty MMR-deficient, nonmethylated endometrial cancers were identified: 3 MLH1/PMS2 and 37 MSH6/MSH2 protein deficiencies. Only 25% occurred in women below 50 years of age (range, 39 to 88 y), 1 of which was in a risk-reducing hysterectomy specimen. Only 15% of patients had a prior history of carcinoma, including only 2 patients with prior colorectal carcinoma. Most (80%) of the endometrial cancers were purely endometrioid; there were 2 mixed endometrioid/mucinous, 1 mucinous, 1 serous, 2 clear cell, and 2 carcinosarcoma cases. When grading was applicable, 40% of the endometrial malignancies were FIGO grade 1, 34% grade 2, and 26% grade 3. Thirteen percent arose in the lower uterine segment, and 23% had tumor-infiltrating lymphocytes. Of the tumors with known germline testing, 41% with a LS-associated germline mutation were not associated with any of the traditional indicators that have been recommended for LS screening (ie, age 50 y or younger, personal/family cancer pedigree that meets Bethesda guideline criteria, presence of MMR-associated tumor morphology, or location in the lower uterine segment). These data suggest that a significant number of LS-associated endometrial carcinomas are missed using clinical, histologic, and locational screening parameters and provide support for universal screening of all newly diagnosed endometrial cancers.

[1]  A. Ariza,et al.  Mismatch repair protein immunohistochemistry: a useful population screening strategy for Lynch syndrome. , 2014, Human pathology.

[2]  A. Karnezis,et al.  Association of Tumor Morphology With Mismatch-repair Protein Status in Older Endometrial Cancer Patients: Implications for Universal Versus Selective Screening Strategies for Lynch Syndrome , 2014, The American journal of surgical pathology.

[3]  Alexander M. Metcalf,et al.  Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Stewart Genetic Testing Strategies in Newly Diagnosed Endometrial Cancer Patients Aimed at Reducing Morbidity or Mortality from Lynch Syndrome in the Index Case or Her Relatives , 2013, PLoS currents.

[5]  C. Eng,et al.  Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center. , 2013, Gynecologic oncology.

[6]  A. Spurdle,et al.  Improving identification of lynch syndrome patients: A comparison of research data with clinical records , 2013, International journal of cancer.

[7]  R. Kuiper,et al.  EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients , 2013, Familial Cancer.

[8]  J. Church,et al.  Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Potter,et al.  Identification of Lynch syndrome among patients with colorectal cancer. , 2012, JAMA.

[10]  B. Clarke,et al.  Identifying Lynch Syndrome in Patients With Endometrial Carcinoma: Shortcomings of Morphologic and Clinical Schemas , 2012, Advances in anatomic pathology.

[11]  J. Weitzel,et al.  Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Clarke,et al.  Use of Mismatch Repair Immunohistochemistry and Microsatellite Instability Testing: Exploring Canadian Practices , 2012, The American journal of surgical pathology.

[13]  Aung Ko Win,et al.  Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Sargent,et al.  Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive, and Therapeutic Implications , 2012, Clinical Cancer Research.

[15]  B. Clarke,et al.  Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation‐positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries , 2012, Cancer.

[16]  J. Ledermann,et al.  Family History and Women With Ovarian Cancer: Is it Asked and Does it Matter? , 2011, International Journal of Gynecologic Cancer.

[17]  Laetitia Huiart,et al.  Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. , 2011, JAMA.

[18]  R. Pai,et al.  A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas , 2011, Modern Pathology.

[19]  Michael S. Rentz,et al.  Immunohistochemical Staining for DNA Mismatch Repair Proteins in Intestinal Tract Carcinoma: How Reliable are Biopsy Samples? , 2011, The American journal of surgical pathology.

[20]  P. Møller,et al.  Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers , 2010, Journal of Medical Genetics.

[21]  H. Hampel Point: justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[22]  B. Karlan,et al.  Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening. , 2010, Gynecologic oncology.

[23]  P. Radice,et al.  Lynch Syndrome—Related Endometrial Carcinomas Show a High Frequency of Nonendometrioid Types and of High FIGO Grade Endometrioid Types , 2010, International journal of surgical pathology.

[24]  Laura H. Tang,et al.  Immunohistochemistry as First-line Screening for Detecting Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer Syndrome: A 2-antibody Panel May be as Predictive as a 4-antibody Panel , 2009, The American journal of surgical pathology.

[25]  A. de la Chapelle,et al.  Identifying Lynch syndrome , 2009, International journal of cancer.

[26]  W. Frankel,et al.  Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer. , 2009, Gynecologic oncology.

[27]  K. Kosarin,et al.  Selection of Endometrial Carcinomas for DNA Mismatch Repair Protein Immunohistochemistry Using Patient Age and Tumor Morphology Enhances Detection of Mismatch Repair Abnormalities , 2009, The American journal of surgical pathology.

[28]  D. Bodurka,et al.  Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Kwon,et al.  Cost‐effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome , 2008, Cancer.

[30]  J. Shia Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. , 2008, The Journal of molecular diagnostics : JMD.

[31]  P. Propping,et al.  Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome , 2008, The Journal of pathology.

[32]  R. Broaddus,et al.  Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  B. Karlan,et al.  Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. , 2007, Gynecologic oncology.

[34]  W. Frankel,et al.  Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. , 2006, Cancer research.

[35]  P. Peltomäki,et al.  Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  W. Frankel,et al.  Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). , 2005, The New England journal of medicine.

[37]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[38]  H. Hollema,et al.  Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Zwinderman,et al.  Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree , 2001, Journal of medical genetics.

[40]  H T Lynch,et al.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. , 1999, Gastroenterology.

[41]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[42]  Alexander M. Metcalf,et al.  Endometrial tumour BRAF mutations and MLH1 promoter methylation as predictors of germline mismatch repair gene mutation status: a literature review , 2013, Familial Cancer.

[43]  Julie O. Culver,et al.  Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. , 2011, The Lancet. Oncology.

[44]  J. Dungan Lynch Syndrome Screening Strategies Among Newly Diagnosed Endometrial Cancer Patients , 2010 .

[45]  R. Coleman Prophylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch Syndrome , 2007 .

[46]  R. Broaddus,et al.  Gynecologic Cancers in Lynch Syndrome/HNPCC , 2005, Familial Cancer.